Millennium
2Q Revenues: $120 million (+9%)
2Q Loss: $17.9 million (loss of $44 million in 2Q2005)
YTD Revenues: $242.6 million (+4%)
YTD Loss: $38.5 million (loss of $80 million YTD2005)
Comments: U.S. Velcade sales increased 34% to $58.8 million in the quarter. Royalties associated with Integrilin Injection worldwide sales and Velcade ex-U.S. sales were $34.2 million for the quarter. Revenue from strategic alliances increased 42% to $27.2 million in the quarter. R&D expenses were down 9% to $79 million in the quarter.
Magazine
